

\* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:18:46 ON 26 APR 2007

=> fil uspatful, caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'USPATFULL' ENTERED AT 16:19:00 ON 26 APR 2007  
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 16:19:00 ON 26 APR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s inflammat? (1s) (cystic fibrosis)  
L1 4116 FILE USPATFULL  
L2 961 FILE CAPLUS

TOTAL FOR ALL FILES  
L3 5077 INFLAMMAT? (1S) (CYSTIC FIBROSIS)

=> s inflammat? (1s) ((cystic or lung or alveolitis) (3a) fibros?)  
L4 5097 FILE USPATFULL  
L5 1533 FILE CAPLUS

TOTAL FOR ALL FILES  
L6 6630 INFLAMMAT? (1S) ((CYSTIC OR LUNG OR ALVEOLITIS) (3A) FIBROS?)

=> s inflammat? (30a) ((cystic or lung or alveolitis) (3a) fibros?)  
L7 3327 FILE USPATFULL  
L8 1309 FILE CAPLUS

TOTAL FOR ALL FILES  
L9 4636 INFLAMMAT? (30A) ((CYSTIC OR LUNG OR ALVEOLITIS) (3A) FIBROS?)

=> s 19 and tiotropium  
L10 135 FILE USPATFULL  
L11 1 FILE CAPLUS

TOTAL FOR ALL FILES  
L12 136 L9 AND TIOTROPIUM

=> d.100-135 kwic, ibib

L12 ANSWER 130 OF 136 USPATFULL on STN

SUMM . . . disorders such as chronic obstructive pulmonary disease (including emphysema), acute respiratory distress syndrome, asthma, hyperoxic alveolar injury and idiopathic pulmonary **fibrosis** and other fibrotic **lung** diseases. It also includes obstructive or **inflammatory** airways diseases of whatever type, etiology, or pathogenesis; or an obstructive or **inflammatory** airways disease that is a member selected from the group consisting of asthma; pneumoconiosis; chronic eosinophilic pneumonia; chronic obstructive pulmonary.

SUMM . . . ethylnorepinephrine hydrochloride; (j)  $\alpha$ .sub.1- and  $\alpha$ .sub.2-adrenoceptor agonists in combination with inhibitors of 5-lipoxygenase (5-LO); (k) anticholinergic agents including ipratropium bromide; **tiotropium** bromide; oxitropium bromide; pirenzepine; and telenzepine; (I) [3- to  $\beta$ .sub.4-adrenoceptor agonists including metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, . . .

ACCESSION NUMBER: 2002:288136 USPATFULL

TITLE: 1,4-dihydropyridine compounds as bradykinin antagonists

INVENTOR(S): Kawamura, Mitsuhiro, UNITED STATES

Kawai, Makoto, UNITED STATES

Shishido, Yuji, UNITED STATES

Kato, Tomoki, UNITED STATES

Katsu, Yasuhiro, UNITED STATES

Ikeda, Takafumi, UNITED STATES

Murase, Noriaki, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002161006	A1	20021031
	US 6653313	B2	20031125
APPLICATION INFO.:	US 2001-903157	A1	20010711 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-224558P	20000810 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4634	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 131 OF 136 USPATFULL on STN

DETD [0010] Within the scope of the present invention the term anticholinergics 1 denotes salts which are preferably selected from among **tiotropium** salts, oxitropium salts and ipratropium salts, most preferably ipratropium salts and **tiotropium** salts. In the above-mentioned salts the cations **tiotropium**, oxitropium and ipratropium are the pharmacologically active ingredients. Within the scope of the present patent application, any reference to the. . . the use of the number 1'. Any reference to compounds 1 naturally also includes a reference to the ingredients 1' ( **tiotropium**, oxitropium or ipratropium).

DETD . . . which may be used within the scope of the present invention are meant the compounds which contain, in addition to **tiotropium**, oxitropium or ipratropium as counter-ion (anion), chloride, bromide, iodide, methanesulphonate or para-toluenesulphonate. Within the scope of the present invention, the. . . methanesulphonate and bromide being of particular importance. Of outstanding importance according to the invention are salts 1 selected from among **tiotropium** bromide,

oxitropium bromide and ipratropium bromide. Ipratropium bromide and **tiotropium** bromide are particularly preferred.

DETD . . . from 1:300 to 50:1, preferably from 1:250 to 40:1. In the particularly preferred pharmaceutical combinations which contain ipratropium salt or **tiotropium** salt as compound 1 and a compound selected from among pramipexol, talipexol and viozan as the dopamine agonist 2, the weight ratios of 1 to 2 are most preferably in a range in which ipratropium or **tiotropium** 1' and 2 are present in proportions of 1:150 to 30:1, more preferably from 1:50 to 20:1.

DETD . . . the scope of the invention thereto, preferred combinations of 1 and 2 according to the invention may contain ipratropium or **tiotropium** 1' and dopamine agonists 2 in the following weight ratios: 1:50; 1:49; 1:48; 1:47; 1:46; 1:45; 1:44; 1:43; 1:42; 1:41; . . .

DETD [0037] If the active substance combination in which 1 denotes **tiotropium** bromide is used as the preferred combination of 1 and 2 according to the invention, the quantities of active substance. . .

DETD [0038] If the active substance combination in which 1 is **tiotropium** bromide monohydrate is used as the preferred combination of 1 and 2 according to the invention, the quantities of 1'.

DETD [0099] **Tiotropium** Bromide:

DETD [0100] The **tiotropium** bromide used in the following formulations examples may be obtained as described in European Patent Application 418 716 A1.

DETD [0101] In order to prepare the inhalable powders according to the invention, crystalline **tiotropium** bromide monohydrate may also be used. This crystalline **tiotropium** bromide monohydrate may be obtained by the method described below.

DETD [0102] 15.0 kg of **tiotropium** bromide are placed in 25.7 kg of water in a suitable reaction vessel. The mixture is heated to 80-90° C. . . kg) moistened with water is suspended in 4.4 kg of water, this mixture is added to the solution containing the **tiotropium** bromide and the resulting mixture is rinsed with 4.3 kg of water. The mixture thus obtained is stirred for at. . .

DETD [0103] Yield: 13.4 kg of **tiotropium** bromide monohydrate (86% of theory).

DETD [0104] The crystalline **tiotropium** bromide monohydrate thus obtained is micronized by known methods in order to prepare the active substance in the form of. . .

DETD [0105]

Ingredients	µg per capsule
-------------	----------------

A) Inhalable powders:

1)

<b>Tiotropium</b> bromide	21.7
Viozan	270
Lactose	4708.3
Total	5000

2)

<b>Tiotropium</b> bromide	21.7
Viozan	45
Lactose	4933.3
Total	5000

3)

<b>Tiotropium</b> bromide + H.sub.2O	22.5
Viozan	495
Lactose	4482.5
Total	5000

4)

<b>Tiotropium</b> bromide	21.7
---------------------------	------

Viozan	400
Lactose	4578.3
Total	5000
5)	
Ipratropium bromide	40
Viozan	270
Lactose	4690
Total	5000
6)	
Ipratropium bromide	20
Viozan	45
Lactose	4935
Total	5000
7)	
<b>Tiotropium</b> bromide	21.7
Pramipexol	400
Lactose	4578.3
Total	5000
8)	
<b>Tiotropium</b> bromide	21.7
Talipexol	400
Lactose	4578.3
Total	5000

DETD [0106] B) Propellant Gas-Containing Aerosols For Inhalation:

	Ingredients	wt. - %
1)	Suspension aerosol:	
	<b>Tiotropium</b> bromide	0.015
	Viozan	0.3
	Soya lecithin	0.2
	TG 134a: TG227 = 2:3	ad 100
2)	Suspension aerosol:	
	Ipratropium bromide	0.015
	Viozan	0.3
	soya lecithin	0.2
	TG 227	ad 100
3)	Suspension aerosol:	
	<b>Tiotropium</b> bromide	0.029
	Viozan	0.45
	absolute ethanol	0.5
	Isopropyl myristate	0.1
	TG 227	ad 100
4)	Suspension aerosol:	
	Ipratropium bromide	0.029

CLM

What is claimed is:

4) A pharmaceutical composition according to claim 1, characterised in that 1 is selected from **tiotropium** salts, oxitropium salts and ipratropium salts.

7) A pharmaceutical composition according to claim 1, characterised in that 1 is selected from **tiotropium** bromide, oxitropium bromide and ipratropium bromide.

48) A method of treating **inflammatory** or obstructive diseases of the respiratory tract, or **cystic fibrosis**, in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition according.

ACCESSION NUMBER:

2002:227622 USPATFULL

TITLE:

Pharmaceutical compositions based on anticholinergics

INVENTOR(S): and dopamine agonists  
 Pairet, Michel, Stromberg, GERMANY, FEDERAL REPUBLIC OF  
 Pieper, Michael P., Ingelheim, GERMANY, FEDERAL  
 REPUBLIC OF  
 Montague Meade, Christopher J., Bingen, GERMANY,  
 FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002122773	A1	20020905
APPLICATION INFO.:	US 2001-27662	A1	20011220 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10063957	20001220
	US 2000-257221P	20001221 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	48	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1016	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L12 ANSWER 132 OF 136 USPATFULL on STN

SUMM . . . juvenile diabetes or diabetes mellitus type 1; anterior uveitis; granulomatous or posterior uveitis; keratoconjunctivitis sicca; epidemic keratoconjunctivitis; diffuse interstitial pulmonary **fibrosis** or interstitial lung **fibrosis**; idiopathic pulmonary **fibrosis**; **cystic fibrosis**; psoriatic arthritis; glomerulonephritis with and without nephrotic syndrome; acute glomerulonephritis; idiopathic nephrotic syndrome; minimal change nephropathy; **inflammatory** /hyperproliferative skin diseases; psoriasis; atopic dermatitis; contact dermatitis; allergic contact dermatitis; benign familial pemphigus; pemphigus erythematosus; pemphigus foliaceus; and pemphigus vulgaris;

SUMM . . . ethylnorepinephrine hydrochloride; (j)  $\alpha$ .sub.1- and  $\alpha$ .sub.2-adrenoceptor agonists in combination with inhibitors of 5-lipoxygenase (5-LO); (k) anticholinergic agents including ipratropium bromide; **tiotropium** bromide; oxitropium bromide; pirenzepine; and telenzepine; (l)  $\beta$ .sub.1- to  $\beta$ .sub.4-adrenoceptor agonists including metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, . . .

DETD . . . juvenile diabetes (diabetes mellitus type I); anterior uveitis and granulomatous (posterior) uveitis; keratoconjunctivitis sicca and epidemic keratoconjunctivitis; diffuse interstitial pulmonary **fibrosis** (interstitial lung **fibrosis**); idiopathic pulmonary **fibrosis**; **cystic fibrosis**; psoriatic arthritis; glomerulonephritis with and without nephrotic syndrome, including acute glomerulonephritis, idiopathic nephrotic syndrome, and minimal change nephropathy; **inflammatory**/hyperproliferative skin diseases including psoriasis and atopic dermatitis discussed in detail further above, contact dermatitis, allergic contact dermatitis, benign familial pemphigus, . . .

DETD . . . juvenile diabetes or diabetes mellitus type I; anterior uveitis; granulomatous or posterior uveitis; keratoconjunctivitis sicca; epidemic keratoconjunctivitis; diffuse interstitial pulmonary **fibrosis** or interstitial lung **fibrosis**; idiopathic pulmonary **fibrosis**; **cystic fibrosis**; psoriatic arthritis; glomerulonephritis with and

without nephrotic syndrome; acute glomerulonephritis; idiopathic nephrotic syndrome; minimal change nephropathy; **inflammatory** /hyperproliferative skin diseases; psoriasis; atopic dermatitis; contact dermatitis; allergic contact dermatitis; benign familial pemphigus; pemphigus erythematosus; pemphigus foliaceus; and pemphigus vulgaris;  
DETD [0629] (i) Anticholinergic agents including ipratropium bromide; **tiotropium** bromide; oxitropium bromide; pirenzepine; and telenzepine;

CLM What is claimed is:

. . . juvenile diabetes or diabetes mellitus type I; anterior uveitis; granulomatous or posterior uveitis; keratoconjunctivitis sicca; epidemic keratoconjunctivitis; diffuse interstitial pulmonary **fibrosis** or interstitial lung **fibrosis**; idiopathic pulmonary **fibrosis**; **cystic fibrosis**; psoriatic arthritis; glomerulonephritis with and without nephrotic syndrome; acute glomerulonephritis; idiopathic nephrotic syndrome; minimal change nephropathy; **inflammatory**/hyperproliferative skin diseases; psoriasis; atopic dermatitis; contact dermatitis; allergic contact dermatitis; benign familial pemphigus; pemphigus erythematosus; pemphigus foliaceus; and pemphigus vulgaris;. . .  
. . . in combination with one or more inhibitors of 5-lipoxygenase (5-LO) as recited in (a) above; (k) Anticholinergic agents ipratropium bromide; **tiotropium** bromide; oxitropium bromide; pirenzepine; and telenzepine; (l)  $\beta$ .sub.1- to  $\beta$ .sub.4-adrenoceptor agonists selected from the group consisting of metaproterenol, isoproterenol, isoprenaline, . . .

ACCESSION NUMBER: 2002:206794 USPATFULL  
TITLE: Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes  
INVENTOR(S): Magee, Thomas Victor, Mystic, CT, UNITED STATES  
Marfat, Anthony, Mystic, CT, UNITED STATES  
Chambers, Robert James, Mystic, CT, UNITED STATES  
PATENT ASSIGNEE(S): Pfizer Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002111495	A1	20020815
APPLICATION INFO.:	US 2002-62811	A1	20020131 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-265240P	20010131 (60)
	US 1997-43403P	19970404 (60)
	US 1998-105120P	19981021 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
LINE COUNT:	7710	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 133 OF 136 USPATFULL on STN

SUMM . . . or hypoxia (including iatrogenic hypoxia) and other forms of reversible pulmonary vasoconstriction. Such pulmonary disorders also are also characterized by **inflammation** of the lung including those associated with the migration into the lung of nonresident cell types including the various leucocyte subclasses. Also included in the respiratory disorders contemplated are **cystic fibrosis** and other diseases which are characterized by excess mucosal secretion. Other physiological events which are contemplated to be controlled include. . .

SUMM . . . pirbuterol, rimiterol, clenbuterol, bitolterol and repreterol, adrenalin, isoproterenol, ephedrine, orciprenlaine, fenoterol and isoetharine); anticholinergic agents (such as atropine, ipratropium, flutropium, **tiotropium** and rispenzepine) and mast cell stabilizers (chromolyn and nedocromil). Selective  $\beta$  agonists have recently been developed with fewer cardiotoxic side. . . .

DETD . . . contemplated  $\beta$ -agonists include salmeterol, albuterol, metaproterenol, terbutaline, pitbuterol, rimiterol, clenbuterol, bitoterol and reproterol. Examples of contemplated anticholinergics include ipratropium, flutropium, **tiotropium** and rispenzepine. Examples of contemplated mast cell stabilizers include cromolyn and nedocromil. Examples of contemplated PDE inhibitors include flamilast, denbufyllene. . . .

ACCESSION NUMBER: 2001:42141 USPTFULL

TITLE: Nitrosated and nitrosylated compounds, and compositions and their use for treating respiratory disorders

INVENTOR(S): Garvey, David S., Dover, MA, United States  
Letts, L. Gordon, Dover, MA, United States  
Renfro, H. Burt, Wellesley, MA, United States  
Richardson, Stewart K., Ashford, CT, United States

PATENT ASSIGNEE(S): NitroMed, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 37116	E1	20010327
	US 5824669		19981020 (Original)
APPLICATION INFO.:	US 1998-219476		19981223 (9)
	US 1996-620882		19960322 (Original)
DOCUMENT TYPE:	Reissue		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
LEGAL REPRESENTATIVE:	Hale and Dorr LLP		
NUMBER OF CLAIMS:	39		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 29 Drawing Page(s)		
LINE COUNT:	1916		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 134 OF 136 USPTFULL on STN

SUMM . . . or hypoxia (including iatrogenic hypoxia) and other forms of reversible pulmonary vasoconstriction. Such pulmonary disorders also are also characterized by **inflammation** of the lung including those associated with the migration into the lung of non-resident cell types including the various leucocyte subclasses. Also included in the respiratory disorders contemplated are **cystic fibrosis** and other diseases which are characterized by excess mucosal secretion. Other physiological events which are contemplated to be controlled include. . . .

SUMM . . . pirbuterol, rimiterol, clenbuterol, bitolterol and repreterol, adrenalin, isoproterenol, ephedrine, orciprenlaine, fenoterol and isoetharine); anticholinergic agents (such as atropine, ipratropium, flutropium, **tiotropium** and rispenzepine) and mast cell stabilizers (chromolyn and nedocromil). Selective  $\beta$  agonists have recently been developed with fewer cardiotoxic side. . . .

DETD . . . contemplated  $\beta$ -agonists include salmeterol, albuterol, metaproterenol, terbutaline, pitbuterol, rimiterol, clenbuterol, bitoterol and reproterol. Examples of contemplated anticholinergics include ipratropium, flutropium, **tiotropium** and rispenzepine. Examples of contemplated mast cell stabilizers include cromolyn and nedocromil. Examples of contemplated PDE inhibitors include flamilast, denbufyllene. . . .

ACCESSION NUMBER: 2001:33259 USPTFULL

TITLE: Nitrosated and nitrosylated steroids compositions, and

INVENTOR(S): methods for treating respiratory disorders  
Garvey, David S., Waltham, MA, United States  
Letts, L. Gordon, Dover, MA, United States  
Renfroe, H. Burt, Wellesley, MA, United States  
PATENT ASSIGNEE(S): Richardson, Stewart K., Ashford, CT, United States  
NitroMed, Inc., Bedford, MA, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6197762	B1	20010306
APPLICATION INFO.:	US 1998-157242		19980918 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-620882, filed on 22 Mar 1996, now patented, Pat. No. US 5824669 Continuation of Ser. No. WO 1997-US4319, filed on 19 Mar 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
ASSISTANT EXAMINER:	Desai, Rita		
LEGAL REPRESENTATIVE:	Hale and Dorr LLP		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 29 Drawing Page(s)		
LINE COUNT:	1841		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L12 ANSWER 135 OF 136 USPATFULL on STN

SUMM . . . or hypoxia (including iatrogenic hypoxia) and other forms of reversible pulmonary vasoconstriction. Such pulmonary disorders also are also characterized by **inflammation** of the lung including those associated with the migration into the lung of nonresident cell types including the various leucocyte subclasses. Also included in the respiratory disorders contemplated are **cystic fibrosis** and other diseases which are characterized by excess mucosal secretion. Other physiological events which are contemplated to be controlled include.

SUMM . . . pirbuterol, rimiterol, clenbuterol, bitolterol and repreterol, adrenalin, isoproterenol, ephedrine, orciprenlaine, fenoterol and isoetharine); anticholinergic agents (such as atropine, ipratropium, flutropium, **tiotropium** and rispenzepine) and mast cell stabilizers (chromolyn and nedocromil). Selective  $\beta$  agonists have recently been developed with fewer cardiotoxic side.

DETD . . . contemplated  $\beta$ -agonists include salmeterol, albuterol, metaproterenol, terbutaline, pitbuterol, rimiterol, clenbuterol, bitoterol and reproterol. Examples of contemplated anticholinergics include ipratropium, flutropium, **tiotropium** and rispenzepine. Examples of contemplated mast cell stabilizers include cromolyn and nedocromil. Examples of contemplated PDE inhibitors include filaminast, denbufyllene.

ACCESSION NUMBER: 1998:128257 USPATFULL  
TITLE: Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders  
INVENTOR(S): Garvey, David S., Dover, MA, United States  
Letts, L. Gordon, Dover, MA, United States  
Renfroe, H. Burt, Wellesley, MA, United States  
Richardson, Stewart K., Ashford, CT, United States  
PATENT ASSIGNEE(S): NitroMed, Inc., Bedford, MA, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5824669		19981020
APPLICATION INFO.:	US 1996-620882		19960322 (8)
DOCUMENT TYPE:	Utility		



FILE SEGMENT: Granted  
PRIMARY EXAMINER: Rotman, Alan L.  
LEGAL REPRESENTATIVE: Hale and Dorr LLP  
NUMBER OF CLAIMS: 19  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 29 Drawing Page(s)  
LINE COUNT: 1812  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

Connection closed by remote host